GlassScriptPhysician profile
Amy Lynn Cavanagh
NPI 1902856776
$8,084.43
in general payments reported to CMS, 2019-2025
26 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $1,132 · 2023: $736 · 2024: $3,667 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,623 · Education: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,622.96 |
| Education | $460.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,230.73 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $929.83 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $887.15 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $644.25 | 2022-2025 | |
| Lilly USA, LLC | $536.63 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $411.51 | 2023-2025 | Winlevi |
| Ucb, INC. | $398.59 | 2023-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $380.85 | 2021-2025 | |
| Amgen INC. | $351.70 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $293.57 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $287.44 | 2023-2025 | Sotyktu |
| Incyte Corporation | $283.64 | 2021-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $265.84 | 2021-2024 | Siliq, Duobrii, Targretin |
| Pfizer INC. | $261.66 | 2021-2024 | |
| Galderma Laboratories, L.P. | $256.84 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $234.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $169.94 | 2021-2024 | |
| Dermavant Sciences, INC. | $74.50 | 2024 | Vtama |
| Organogenesis INC. | $46.09 | 2024 | Affinity |
| Verrica Pharmaceuticals INC. | $34.77 | 2024 | Ycanth |
| Botanix Sb INC | $26.54 | 2025 | Sofdra |
| Biofrontera INC. | $20.39 | 2025 | |
| Vyne Pharmaceuticals INC. | $18.21 | 2021 | |
| Kyowa Kirin, INC. | $17.47 | 2025 | |
| Journey Medical Corporation | $16.61 | 2025 | |
| Organon LLC | $5.32 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cavanagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.